Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05064397 · ClinicalTrials.gov registry record · Phase 3
A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)
A Phase 3 study, sponsored by H. Lundbeck A/S.
- Completed
- Registry status
- Phase 3
- Development phase
- 131
- Enrollment target
NCT05064397 is a Phase 3 study that has completed, run by H. Lundbeck A/S. The registered enrollment target is 131 participants.
The verdict
NCT05064397, a Phase 3 study, has completed, sponsored by H. Lundbeck A/S.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 131 participants
- Enrollment target
Study Summary
The main goal of this trial is to inform about long-term safety and tolerability of eptinezumab in participants with chronic cluster headache.
Interventions
- DRUG Eptinezumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2021-09-17 |
| Est. Completion | 2023-06-29 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05064397
The ClinicalTrials.gov registry entry for NCT05064397 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is H. Lundbeck A/S, which has 72 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Eptinezumab is the first listed.
NCT05064397 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05064397 about?
NCT05064397 is a clinical study titled "A 1-year Trial to Inform About Long-term Exposure to Eptinezumab in Participants With Chronic Cluster Headache (cCH)". The main goal of this trial is to inform about long-term safety and tolerability of eptinezumab in participants with chronic cluster headache.
What is the current status of trial NCT05064397?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 131 participants. The study started on 2021-09-17. Estimated completion is 2023-06-29.
What interventions are being tested in trial NCT05064397?
The interventions under investigation include: Eptinezumab (DRUG).
Who is sponsoring clinical trial NCT05064397?
This trial is sponsored by H. Lundbeck A/S, which has 72 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.